APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 2.25 mg - tablet, modified release - excipient ingredients: silicon dioxide; magnesium stearate; hypromellose; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

PRAMIPEXOLE XR GP pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

pramipexole xr gp pramipexole dihydrochloride monohydrate 2.25 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 2.25 mg - tablet, modified release - excipient ingredients: hypromellose; calcium hydrogen phosphate; silicon dioxide; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

SIMPRAL pramipexole dihydrochloride monohydrate 0.125 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

simpral pramipexole dihydrochloride monohydrate 0.125 mg tablet blister pack

alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.125 mg - tablet - excipient ingredients: hyprolose; sodium citrate; crospovidone; magnesium stearate; mannitol; pregelatinised maize starch; colloidal anhydrous silica - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.

SIMPRAL pramipexole dihydrochloride monohydrate 0.25 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

simpral pramipexole dihydrochloride monohydrate 0.25 mg tablet blister pack

alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet - excipient ingredients: crospovidone; colloidal anhydrous silica; mannitol; sodium citrate; pregelatinised maize starch; hyprolose; magnesium stearate - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 3 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 3 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3 mg - tablet, modified release - excipient ingredients: silicon dioxide; calcium hydrogen phosphate; hypromellose; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3.75 mg - tablet, modified release - excipient ingredients: calcium hydrogen phosphate; hypromellose; silicon dioxide; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 0.375 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 0.375 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.375 mg - tablet, modified release - excipient ingredients: calcium hydrogen phosphate; hypromellose; magnesium stearate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 0.75 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 0.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.75 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; calcium hydrogen phosphate; silicon dioxide - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 4.5 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 4.5 mg - tablet, modified release - excipient ingredients: silicon dioxide; magnesium stearate; hypromellose; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

APO-PRAMIPEXOLE ER pramipexole dihydrochloride monohydrate 1.5 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-pramipexole er pramipexole dihydrochloride monohydrate 1.5 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet, modified release - excipient ingredients: silicon dioxide; hypromellose; magnesium stearate; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.